Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock By Investing.com

Snehal Patel, the Chief Executive Officer and Chief Financial Officer of Greenwich LifeSciences, Inc. (), recently purchased shares of the company’s common stock. The transactions, which took place on July 28 and July 29, 2026, totaled $29,555. The shares were acquired at prices ranging from $13.10 to $13.59 per share.

On July 28, Mr. Patel purchased 1,500 shares at a price of $13.59 each. The following day, July 29, he acquired an additional 700 shares for $13.10 per share. In total, Mr. Patel, who also serves as a Director and 10% Owner of the company, purchased 2,200 shares.The insider purchases come as the stock has declined 57% over the past six months, currently trading at $12.80. According to InvestingPro analysis, GLSI appears overvalued relative to its Fair Value, though analysts maintain bullish price targets ranging from $45 to $69.

Following these transactions, Mr. Patel directly beneficially owns 5,611,402 shares of Greenwich LifeSciences common stock.

In other recent news, Greenwich LifeSciences Inc. announced modifications to its Phase III clinical trial, FLAMINGO-01, following a regulatory review by the FDA and EMA. The trial, which evaluates GLSI-100, an immunotherapy for preventing breast cancer recurrences, was recommended to continue without modifications by the company’s Data Safety Monitoring Board. Additionally, the European Medicines Agency approved the inclusion of both HLA-A02 and non-HLA-A02 patients in the trial, aligning all 170-180 clinical sites in the U.S. and Europe under the same protocol. The EMA also cleared the use of commercially manufactured GP2 for the trial, with shipments to European pharmacies already underway. At the ASCO Annual Meeting, Greenwich LifeSciences presented preliminary immune response data from 247 patients in the non-HLA-A02 arm of the trial. Meanwhile, the company announced a delay in its Form 10-K filing for the fiscal year ending December 31, 2025, citing coordination requirements between two auditors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.